AcelRx Pharma (ACRX) Reports In-Line Q3 EPS

AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.9 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Movano (MOVE) Misses Q2 EPS by 195c